TRINITY – targeted repurposing of JAK inhibitors across autoimmune pathology
General Audience Summary
The project TRINITY investigates how the immune systems of people with type 1 diabetes (T1D), lupus (SLE), and multiple sclerosis (MS) respond to inflammatory signals that cause the body to attack itself. Although these diseases affect different organs, they share common immune pathways, and people with the same disease often respond very differently to treatment. This makes it challenging to identify therapies that are both effective and safe. Rather than focusing on broad immune overactivation, TRINITY concentrates on specific immune signaling pathways that may be driving disease in different ways. The project builds on earlier research showing that immune cells from people with SLE and MS are highly metabolically active, while immune cells from people with T1D look much more like those of healthy individuals. In T1D, however, immune cells show subtle but important changes in how they respond to inflammatory signals, particularly those involving the immune messenger interleukin-7 (IL-7). IL-7 sends signals through a communication system inside immune cells known as the Janus kinase (JAK)/STAT pathway. This pathway helps control immune cell survival, activation, and function and plays an important role in autoimmune disease.
The project TRINITY will test five already-approved JAK inhibitor medications which block different parts of this pathway, to determine how effectively they can calm harmful immune responses across T1D, SLE, and MS. By studying immune cells from people with all three autoimmune diseases side by side, TRINITY aims to identify which immune signals are shared and which are disease-specific. Using the same laboratory methods across all groups allows researchers to directly compare how different JAK inhibitors affect immune cell activation, inflammation, and survival under controlled conditions. This approach helps reveal why certain drugs may work better in one disease than another. Because these JAK inhibitor medications are already approved for use in humans, TRINITY’s findings could quickly support their repurposing for autoimmune diseases where treatment options remain limited. In particular, the TRINITY seeks to identify drugs that may help protect insulin-producing cells in T1D while also reducing damaging immune activity in lupus and MS. Overall, TRINITY aims to provide a clearer understanding of how immune signaling drives autoimmune disease and to use this knowledge to guide more targeted and personalized treatments. By focusing on shared immune mechanisms rather than disease labels alone, the project TRINITY has the potential to accelerate the development of safer and more effective therapies for people living with autoimmune conditions.
Scientific Abstract
Autoimmune diseases such as type 1 diabetes (T1D), systemic lupus erythematosus (SLE) and multiple sclerosis (MS) share immune-mediated pathology but exhibit marked heterogeneity in underlying mechanisms and therapeutic responses. Limited mechanistic understanding and patient heterogeneity slow down effective treatment stratification and clinical trial success. Building on extensive preliminary work from the COMET consortium, TRINITY aims to identify shared and disease-specific immune signaling pathways that drive these conditions, with a particular focus on Janus kinase (JAK)/STAT dependent cytokine signaling rather than global metabolic immune activation.
Integrative immunometabolic, phenotypic and transcriptomic analyses from the preceding COMET project revealed a fundamental difference in autoimmune pathomechanisms: Immune cells from MS and SLE display pronounced metabolic hyperactivation, whereas peripheral immune cells from T1D resemble healthy controls metabolically, but show selective dysregulation of interleukin-7 (IL-7) receptor signaling. As IL-7 signaling is dependent on JAK1/JAK3 activity, this pathway represents a compelling therapeutic node across these diseases, particularly for T1D, where recent clinical trials have demonstrated beta cell preservation with JAK inhibition. TRINITY will systematically evaluate the effects of up to five approved JAK inhibitors, including baricitinib, deucravacitinib, and ritlecitinib, on immune cells derived from patients with T1D, SLE, and MS. Using a combination of high content phenotypic screening, phosphor flow cytometry and cytokine response assays under defined inflammatory stress conditions, the project TRINITY will assess how selective JAK inhibition reshapes immune signaling, survival and pro-inflammatory activation thresholds across diseases.
Overall, TRINITY seeks to identify key shared and disease-specific vulnerabilities within the JAK/STAT axis. The project will provide a proof of concept that comparative, mechanism-based immune profiling can rationally inform the targeted repurposing of approved JAK inhibitors across different autoimmune diseases. By defining how disease-specific immune cell states and signaling dependencies shape responsiveness to JAK inhibition, TRINITY will contribute to future biomarker development, mechanism-based patient stratification and subsequent clinical validation. Ultimately, this integrative framework will support the systematic expansion of selected JAK inhibitors into new autoimmune indications through data-driven clinical translation.